Metlinka

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metlinka, is a Biguanide; DPP‑4 inhibitor presented as a tablet for oral use. It helps control blood glucose levels in adults with type 2 diabetes mellitus, often used when diet, exercise, and monotherapy are insufficient.

GNH USA supplies Metlinka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Products are manufactured in EU‑approved facilities and undergo full batch release testing before distribution.

Metlinka, a fixed‑dose combination of metformin and sitagliptin, is indicated for managing hyperglycemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. - Inadequate control on metformin monotherapy: provides additional DPP‑4 inhibition to lower glucose. - Inadequate control on sitagliptin monotherapy: adds metformin to reduce hepatic glucose production.

Metlinka may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Headache: mild cranial discomfort. - Upper respiratory tract infection: cold‑like symptoms. - Abdominal discomfort: general stomach pain. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes. - Acute kidney injury: sudden loss of kidney function.

Before prescribing Metlinka, clinicians should evaluate patient-specific risk factors and monitor for complications. - Renal function: assess baseline creatinine clearance and monitor periodically. - Lactic acidosis risk: avoid in patients with severe renal impairment or metabolic acidosis. - Hypoglycemia risk: monitor closely when used with insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Cardiovascular disease: monitor for heart failure symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metlinka can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Phenformin or other contraindicated biguanides: increased risk of lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): elevate sitagliptin plasma levels. - Iodinated contrast agents: may precipitate renal impairment when combined with metformin.

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened risk of hypoglycemia. - Diuretics (thiazides): may affect renal clearance of metformin. - Beta‑blockers: can mask symptoms of hypoglycemia.